Ocata Therapeutics Inc fka OCAT

[rocky301]

The highlighted print in paragraph below is new additional info when compared to 10K...


(page 33 of recently filed S-1)
Retinal Pigment Epithelium Program. In November, 2006 we published data demonstrating human ES cell-derived RPE cells were capable of rescuing visual function in Royal College of Surgeon rats. Following the publication of that data, we entered into a pre-clinical development collaboration with Casey Eye Institute at Oregon Health & Science University. The purpose of the collaboration is to conduct dosage and safety studies in preparation for IND and Phase I human clinical trials.
In June 2009 the Company, along with its collaborators published results of the Long-term Safety and Function of RPE from Human Embryonic Stem Cells in Preclinical Models of Macular Degeneration. In parallel the Company entered into a Master Service Agreement with Sinclair Research of Auxvasse, MO to perform a Biodistribution and Safety/Tumorgenicity Study to further support these results.

Sinclair Research:
http://www.sinclairresearch.com/AboutUs/Default.aspx